Excellent post. Clear, to the point and well balanced.
I too have come to the conclusion that MBP is worthy of my money, albeit by a less mathematical route. The proof of AOD9604 efficacy in the treatment of obesity will not be proved conclusively until phase 3 testing is complete and analysed. However, I do not think that the company would pursue the obesity uses of the AOD9604 drug (there is also prospective uses for it in treating osteoporosis) without having confidence in the outcome of the phase 2B trial. If they thought/knew it would fail they would simply apply their monies and efforts in developing their other prospective compounds they have in the pipeline, all of which also have large potential markets.
MBP Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
